Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers

Tiacci, 2015, Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia., N Engl J Med, 373, 1733, 10.1056/NEJMoa1506583

Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation., N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782

Hyman, 2015, Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations., N Engl J Med, 373, 726, 10.1056/NEJMoa1502309

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade., Science, 357, 409, 10.1126/science.aan6733

Chalmers, 2017, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden., Genome Med, 9, 34, 10.1186/s13073-017-0424-2

@adamfeuerstein. How soon before we no longer refer to breast, lung, colon cancer, but instead only describe genetic makeup of cancer? Is that possible? May 23, 2017. https://twitter.com/adamfeuerstein/status/867095289127153664?lang=en. Accessed November 3, 2017.

Merck & Co. Highlights of Prescribing Information: KEYTRUDA. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pd. Accessed November 3, 2017.

American Cancer Society. Cancer Facts and Figures, 2017. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. Accessed November 3, 2017.